Furthermore, 4EGI-1 demonstrated synergy with the BCL2 inhibitor ABT-737 to enhance apoptosis in CLL and improve sensitivity to gemcitabine in non-small cell lung cancer (NSCLC) in vitro [205]. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.